Role of MicroRNAs in Rheumatoid Arthritis by Birlik, Merih et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
Chapter 2
Role of MicroRNAs in Rheumatoid Arthritis
Merih Birlik, Ayşe Koçak and Duygu Harmancı
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/67081
© 2016 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons 
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, 
and reproduction in any medium, provided the original work is properly cited. 
Merih Birlik, Ayşe Koçak and Duygu 
Harmancı
Additional information is available at the end of the chapter
Abstract
Rheumatoid arthritis (RA) is a common autoimmune disease. The hallmarks of RA are 
synovial inflammation and hyperplasia, autoantibody production, systemic features, and 
deformity. A lot of researchers have paid attention to the possibility that microRNAs 
(miRNAs) play a role in the pathogenesis of RA. miRNAs are a class of small noncod-
ing RNAs, which have 18–25 nucleotides. These small RNAs modify gene expression by 
binding to target messenger RNA (mRNA), and they block the translation or induce the 
degradation of target mRNA. Biological relevance of miRNAs has been investigated in 
physiological and pathological conditions. A growing body of evidence suggests that 
miRNAs participate in the inflammatory disorders including RA. In this chapter, an over-
view of biogenesis and function of miRNAs has been presented to introduce researchers 
to the changes and functional regulation of the key miRNAs in RA and to provide current 
knowledge in miRNA and RA. It is important to understand the relationship between the 
key miRNAs and RA pathology as modulation of specific miRNA alterations could be of 
great pharmaceutical interest in the future.
Keywords: microRNA, miRNA, small noncoding RNA, rheumatoid arthritis, 
pathogenesis
1. Introduction
Rheumatoid arthritis (RA) is an autoimmune disease characterized by chronic synovial 
inflammation exemplified by cell hyperplasia, autoantibody production, systemic features, 
and deformity [1–3]. It affects approximately 0.36–2.0% of the human population worldwide 
and roughly three to four times more females than males [2, 4]. RA progression is a complex 
process and consists of many genes and environmental factors [3]. Accumulating clinical and 
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experimental evidence points out that the immune system plays a key role in disease patho-
genesis. However, pathogenesis of RA is not entirely clear [1–3]. Generally, RA progression 
leads to joint destruction, functional disability, and cardiovascular comorbidities [5]. The 
immune system and different cell types such as macrophages, T and B cells, and synovial 
fibroblasts participate in the pathogenesis of RA. RA synovial fibroblasts and “fibroblast-like 
synoviocytes” (FLS) play an important role in RA [6, 7].
Genetic and environmental factors are associated with RA. These factors include infectious 
agents, exposure to cigarette smoke, air pollution, insecticides, and occupational exposures 
to mineral oil and silica. But so far, smoking is the only environmental risk factor that has 
been extensively studied and widely accepted [3]. When environmental factors are consid-
ered some of them can be controlled, but the control of genetic and epigenetic regulation 
is highly complex and difficult to predict. The contribution of epigenetic gene regulation is 
considerably less well established. Epigenetics is a mechanism that regulates gene expres-
sion independently of the underlying DNA sequence. In early 2000s, with the discovery 
of micro RNAs (miRNAs), researchers have started to discuss their roles in physiological 
and pathologic processes [8]. miRNAs are small noncoding RNAs 18–25 nucleotides in 
length that block the translation or induce the degradation of target mRNA [9]. The clini-
cal application of epigenomic information has improved in recent years. A growing body 
of evidence suggests that miRNAs participate in the inflammatory disorders including RA 
[10–12].
In this chapter, we summarize the biogenesis and function of miRNA, with an emphasis of its 
role in the pathogenesis and the importance of miRNA in RA as a potential biomarker.
2. What are microRNAs?
The small RNAs are crucial for the cellular gene regulatory systems. Over the last decade, 
these small RNAs have become important regulators in eukaryotic genomes. These noncod-
ing RNAs regulate genes and genomes. This regulation includes chromatin structure, tran-
scription, RNA processing, RNA stability, and translation. Generally, the small RNAs show 
inhibitory activity on gene expression. One type of these small RNAs is microRNAs [13].
MicroRNAs (miRNAs) are small endogenous noncoding RNAs [13]. In 1993, Ambros and 
his collaborators discovered the first miRNA, lin-4 from Caenorhabditis elegans. Researchers 
studied the postembryonic development of C.elegans and found two noncoding RNAs which 
were produced by lin-4 with complementary sequences to the 3′UTR (un-translated region) of 
lin-14 mRNA [14]. These small transcripts could bind the 3′UTR of lin-14 mRNA and decrease 
protein levels without affecting mRNA stability. In early 2000s, Reinhart (and) et al discov-
ered the second miRNA, let-7, and following this discovery, more than a dozen miRNAs were 
found in plant and animal species in 2000s [15–18]. The name “microRNA” was first used in 
2001, and papers published in science reported that there were up to 50 miRNAs [19–22]. The 
brief history of miRNAs is reviewed in Figure 1.
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miRNAs are short (about 18–25 nucleotides long) noncoding RNAs that can affect messen-
ger RNA (mRNA) processing at the post-transcriptional level [15]. They are endogenous and 
goal-oriented expressed products of an organism’s own genome [13]. Chromosomal locations 
of miRNAs affect the expression and function themselves [23]. According to their genomic 
localizations, miRNAs can be classified into five groups [24]:
1. Intergenic miRNAs (miRNA genes are located between two consecutive protein-coding 
genes).
2. Intronic miRNAs in noncoding transcripts (miRNA genes are located in any intron of a 
noncoding RNA gene).
3. Intronic miRNAs in protein-coding transcripts (miRNA genes are located in any intron of 
a protein-coding RNA gene).
4. Exonic miRNAs in noncoding transcripts (miRNA genes are located in any exon of a non-
coding RNA gene).
5. Exonic miRNAs in protein-coding transcripts (miRNA genes are located in any exon of a 
protein-coding RNA gene).
Figure 1. The brief history of miRNAs.
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Some miRNAs are located in every second group because of alternative splicing [9]. Intergenic 
miRNAs are transcribed from their own promoters but intragenic miRNAs generally located 
in the same orientation as the host genes [24] (Figure 2).
The scientific denomination rule is simple for the miRNAs. The mature miRNA is abbrevi-
ated with a capitalized “miR-” while the uncapitalized “mir-” indicates both the gene locus 
and precursor miRNA (pre-miRNA and pri-miRNA). Every miRNA is named according to 
discovery order, and "MIR" refers to the gene that encodes them. The numbering of miRNA 
genes is simply sequential. For example, miR-21 was discovered before the miR-155 [10]. In 
addition, three letters specific for each species precede each name. Thus “hsa-miR155” means 
that this miR origins from Homo sapiens while ggo-mir-155 is an example of gorilla's miRNA 
name. A letter after the number in the suffix is used to differentiate among multiple members 
of the same family (e.g., hsa-mir-155a and hsa-mir-155b). Today, miRNAs is still a popular 
subject for the researchers and have been studied in many organisms. Some miRNA databases 
(http://www.mirbase.org/, http://mirdb.org/miRDB/, http://www.microrna.org/microrna/
home.do and so forth) are available and every moment the miRNA list is updated [25, 26].
3. miRNA biogenesis
In the early 2000s, the scientific world discovered small RNAs. They work as gene regulators, 
but their biogenesis is still unclear. Most mammalian miRNA genes are located in the intron 
region; some are located in the exon region and also approximately 30% are located in the 
intergenic regions. Since 2000, the miRNA biogenesis pathway has been studied and in 2001, 
Mello and his colleagues obtained the first data [17].
Figure 2. The genomic organization of miRNAs.
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Generally, mammalian miRNA biogenesis pathway can be divided into two main parts 
with regard to processing pri-miRNAs: canonical and noncanonical [27]. In the canonical 
miRNA biogenesis pathway, the pri-miRNA is processed to pre-miRNA in the nucleus. In 
the noncanonical miRNA biogenesis pathway, mirtrons participate in microprocessor pro-
cessing as alternative miRNA precursors. There are some differences between pri-miRNAs 
and mirtrons. Mirtrons arise from the spliced-out introns and lack lower stem loop struc-
ture and the flanking single-stranded segments thus the mirtrons bypass Drosha processing 
[28, 29].
The canonical miRNA biogenesis pathway is Drosha and Dicer dependent. Drosha is a mem-
ber of ribonuclease III enzyme family, and the core nuclease that initiates miRNA processing 
in the nucleus [16]. Dicer is also a member of RNAse III family. It cleaves double-stranded 
RNA (ds-RNA) and precursor miRNA (pre-miRNA) into short dsRNA fragments. Dicer 
forms the mature miRNA in the cytoplasm [16, 18]. The noncanonical miRNA biogenesis 
pathway is Drosha independent/Dicer dependent. Here, microprocessor is not required. 
Mirtrons are a type of miRNA that are direct Dicer substrates. A number of noncanonical 
pathways have been described, but most pathways remain unclear. Besides, mirtrons com-
prise small part of the miRNAs, so generally miRNAs are processed via canonical pathway 
[16, 18, 27].
Microprocessor components, Drosha, DiGeorge critical region 8 (DGCR8, also known as 
Pasha), and Dicer, are essential for the canonical miRNA biogenesis, and the biogenesis 
pathway is compartmentalized and stepwise [27]. The canonical mRNA biogenesis pathway 
starts with RNA Pol II-mediated transcription of genomic region containing miRNA genes. 
Transcripts (pri-miRNAs) are capped (at the 5′ end) and polyadenylated (at the 3′ end). The 
pri-miRNAs are cleaved to pre-miRNA hairpins by RNAse III enzyme Drosha in the nucleus. 
DGCR8 (Pasha) proteins accompany this processing. Then, pre-miRNAs are exported from 
the nucleus to cytoplasm by exportin-5 (XPO-5) via Ran-GTP–dependent mechanism. In the 
cytoplasm, pre-miRNA is processed into a mature miRNA. RNAse III Dicer cleaves the pre-
miRNA together with trans-activation response RNA binding protein (TRBP)/protein acti-
vator of PKR (PACT) proteins to produce unstable, 18–22 nt asymmetric miRNA:miRNA* 
duplex.
miRNA represents guide RNA strand, and the other miRNA* means passenger RNA 
strand. The guide RNA strand incorporates into RNA-induced silencing complex (RISC), 
and passenger RNA strand is discarded. Argonaute (AGO) is one of the key components 
of RISC for this process [18, 27]. The canonical miRNA biogenesis pathway is summarized 
in Figure 3.
The alternative miRNA biogenesis pathways are named noncanonical pathways. These path-
ways do not require all enzymes and protein factors of the canonical pathway. Some miRNAs 
differ from the others in terms of structure and function and these miRNAs bypass one or 
more steps of miRNA canonical biogenesis [27, 29]. Dicer is required for both pathways—
canonical and noncanonical, but Drosha and DGCR8 are only needed for the canonical path-
way. If there is a mutation or deficiency of these enzymes, miRNA biogenesis goes on via the 
noncanonical pathway. The noncanonical miRNA biogenesis pathway can be divided mainly 
into two classes [27, 30].
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3.1. Drosha/DGCR8-independent/Dicer-dependent pathways
3.1.1. Mirtron pathway
Some introns form short RNA hairpins, and they are termed “mirtrons” that can be spliced 
resulting in a nonlinear intermediate. Investigations of the data of small RNAs from 
Drosophila melanogaster and Caenohabditis elegans led to the discovery of mirtrons [28]. 
They can be debranched into pre-miRNA hairpins and form the duplex. After this step, this 
product can join he (the) canonical pathway and is ready to be transported to the cytoplasm 
by exportin-5 (EXP-5) [29].
Depending on the splice donor and acceptor site, mirtrons can be categorized into three 
groups: 5′-tailed mirtron, regular mirtron, and 3′-tailed mirtron. Generally, 3′-tailed mirtrons 
have been found in Drosophila, and 5′-tailed mirtrons have only been described in vertebrates 
[28, 29]. Mirtrons being a new research area, there are many unanswered questions.
3.1.2. snoRNA-derived RNAs (sdRNAs)
Small-nucleolar RNAs are a class of noncoding RNAs. Generally, they show similar proper-
ties and structures to miRNAs. They are dependent on Dicer and can be bound with AGO 
acting as a miRNA [29, 31].
Figure 3. The canonical miRNA biogenesis pathway.
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3.1.3. miRNAs from tdRNAs
The first (tdRNA) tRNA-derived RNA species to be discovered were isoleucine tRNA-
derived miRNA [27]. Normally, they differ from regular miRNAs but they have RNA 
silencing function. tRNA-derived (tdRNA) precursors can be a potential substrate of Dicer 
because of their different folding form [29, 31]. In the light of this information, they have dif-
ferent properties from typical mammalian miRNAs, and their pattern of behavior remains 
a puzzle.
3.1.4. miRNAs from endogenous short hairpin RNAs (shRNAs)
Several studies have shown that some shRNAs could join the noncanonical miRNA-process-
ing pathway. Normally, in the canonical miRNA pathway, pre-miRNAs hairpins are con-
served and thus can be recognized by microprocessor complex. However, shRNA-derived 
miRNAs do not have the microprocessor sequence. For this reason, they are DiGeorge critical 
region-8 (DGCR-8) independent [27, 29]
3.2. Drosha/DGCR8-dependent/Dicer-independent pathways
Some miRNAs mature in a different way. One of them is miR-451. MiR-451 maturation occurs 
without Dicer. Initially, pri-miR-451 is cleaved by Drosha/DGCR8 to form pre-miRNA duplex. 
But it is too short to present to Dicer as a substrate, so directly it interacts with AGO proteins 
[29, 31]. The miRNA biogenesis pathways and their regulation have been studied extensively 
in last 10 years, but further information is required for miRNA processing.
4. miRNA function
The functions of miRNAs are post-transcriptional repression and degradation of mRNAs 
[13]. They have different expression patterns and regulate several biological and patho-
logical processes [16, 32, 33]. The major function of miRNAs is protein synthesis inhibition. 
They can maintain this function either by inhibition of translation or by mRNA degrada-
tion [34, 35]. The miRNA-mRNA interaction is important for miRNA function, and each 
mature miRNA interacts with specific miRNA/miRNAs. Generally, the interaction takes 
place between the miRNA seed region and 3′ UTR of mRNA for the inhibition of target 
mRNA. There are a few exceptions about miRNA binding sites. In some cases, the miRNA-
mRNA interaction occurs at the 5′-UTR. The second issue is miRNA’s tissue specificity. 
MiRNAs are expressed in a tissue-specific fashion, and also, the action of miRNA is tissue 
specific [36–39].
Identification of miRNA target genes is crucial for the functional characterization of miRNAs. 
Recently, we can predict the target gene with the help of some bioinformatics algorithms and 
software. The most popular software is TargetScan [5, 10]. If in silico analysis is insufficient, 
further analysis can be needed. Some genetic or biochemical methods are preferable. The suc-
cess of the prediction is important to understand miRNA function.
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The miRNAs have a part as an adaptor for miRISC to recognize and regulate target mRNAs. 
MiRISC regulates the translation of AGO proteins by introducing silencing through mRNA 
deadenylation, degradation, or translation [13]. miRNAs which are integrated into the RISC 
complex control the gene expression the level of post-transcription by reducing miRNA sta-
bility or inhibiting translation of mRNA [9, 32, 40]. Besides, miRNAs can affect several epigen-
etic regulators (DNA methyltransferases and histone deacetylases) [16].
In addition to mRNAs repression, some miRNAs have positive effects on gene expression 
[9]. This can occur directly or indirectly. For instance, miR-373 binds to the promoter of 
E-cadherin directly and increases the function of RNA polymerase. If its target mRNA does 
not consist of poly (A)-tail, AGO2 activates the gene expression [8, 9].
The selectivity in gene regulation mechanism depends on the degree of the match occurred 
between target mRNA and miRNA. Exact match is usually found in plants. miRISC complex 
which make partial matches is required to make an exact match with the seed region in the 
related to miRNA to inhibit the translation [41, 42]. Although many miRNAs cause of gene 
silencing by reducing the target mRNA stability, some miRNAs lead to gene silencing by 
inhibiting target mRNA translation, but there is not enough evidence about what stage they 
repress. In general, studies suggest that miRNAs repress the translation with four different 
mechanisms: (1) suppression of protein synthesis, (2) a drop of premature mRNAs in ribo-
somes, (3) slowing down during the alongation step of protein synthesis, (4) in parallel with 
protein synthesis the fragmentation of protein [40, 43, 44].
The function of miRNAs has been studied since the first two microRNAs discovered. miR-
NAs are considered key regulators to physiological processes, such as cellular and tissue dif-
ferentiation, apoptosis, innate, and adaptive immune responses and development [13, 17, 35, 
45, 46]. Thus, miRNAs are crucial for the regulation of biological processes [17]. Deregulation 
of this regulatory network can lead to the initiation of undesired pathological processes, such 
as cancer, fibrotic diseases, and autoimmune diseases [17, 35, 45, 46].
miRNAs have essential roles in immune system as they arrange innate and adaptive immune 
systems and have pivotal roles in the regulation of inflammation, by controlling the differen-
tiation of B cells, conventional T cells, and regulatory T cells [11, 39].
4.1. Innate immunity and miRNAs
The innate immune system fights microorganisms. It has many cell types, which are physical 
epithelial barriers, phagocytic leukocytes, dendritic cells, natural killer (NK) cells, and circu-
lating plasma proteins. Pattern recognition receptors (PRRs) recognize microorganisms and 
include toll-like receptors (TLRs), C-type lectin-like receptors (CLRs), retinoic acid-inducible 
gene (RIG)-I-like-receptors (RLRs) and nucleotide-binding oligomerization domain (NOD)-
like receptors (NLRs). This process starts to intracellular signaling pathways. TLR has 10 sub-
types such as TLR1, TLR2, TRL3, TLR4, TLR5, TLR6, TRL7, TRL8, TRL9, and TLR10 [47–50]. 
TLR4 identify lipopolysaccharides (LPSs). miR-146a/b, miR-132, and miR-155 are overex-
pressed for the LPS-mediated inflammatory responses. miR-146 upregulation causes interleu-
kin-1 receptor-associated kinase (IRAK) 1 and genes expression and tumor necrosis factors 
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receptor–associated factor (TRAF) 6 [51]. miR-146 was investigated in in vitro model of mouse 
macrophages, and it is a negative regulator of IRAK1, IRAK2 and TRAF6 [52]. On the other 
hand, miR-155 and miR-125b levels are related to TNF-α secretion in mouse macrophages. 
Regulation of miR-155 and miR-125b is LPS/TNF-α dependent; therefore, it is suggested that 
they are new targets of drug design. miR-155 increases TNF-α translation, Fas-associated death 
domain protein (FADD), IkappaB kinase epsilon (IKKepsilon), and TNFR superfamily-inter-
acting serine–threonine kinase 1 (Ripk1) [53]. One study showed that miR-147 increased in 
murine macrophages after stimulation with TLR2, TLR3, and TLR4 ligands and in the lungs 
of mice after LPS exposure [54]. Also, NF-κB is regulated by miR-1303. Mir-1303 regulates the 
process of autophagy related to mycobacteria by targeting Atg2B [55]. Besides, miR-146a and 
miR-155 affect IFN-type I synthesis by TLR-7 and TLR-9, some miRNAs such as miR-126, miR-
21, miR-146a, miR-155, and miR-1246 can mediate regulation with epigenetic modification [56].
4.2. Adaptive immunity and miRNAs
T and B-lymphocytes are major cellular components of the adaptive immunity. As previously 
described, Dicer enzymes are important in the biogenesis of miRNA. In B cells, miR-181b and 
miR-148a play role as miR-148a inhibits the expression of the autoimmune suppressor Gadd45α 
[57, 58]. In T cell early development, decrease of Dicer leads to reduction of T cell numbers both 
in the thymus and peripheral lymphoid organs [59]. In early B cell development, miR-17 defi-
ciency induced by ablation of Dicer in pro-B cells affected B cell antibody diversity and B cell sur-
vival [60]. miR-326 and miR-155 are related to IL-17 [61]. Moreover, miR-155 expression related 
to Th17 cell production and miR-155 downregulated the LPS-induced inflammatory process 
[62, 63]. miR-146 has an essential role in the adaptive immune system. In the Treg cells miR-146 
is an activator of STAT1 transcription that is associated with Th1-mediated autoimmunity [64].
Many studies in animal (many researches on animal olabilir) models and clinical studies 
showed that miRNAs participate in the inflammation and autoimmune diseases mecha-
nisms. In humans, loss of miRNA expression related of the many autoimmune conditions. 
Especially, multiple sclerosis (MS), osteoarthritis, and rheumatoid arthritis (RA) are most 
studied (are the most).
5. Expression profiles of miRNAs in rheumatoid arthritis patients
RA, characterized by chronic joint inflammation, is an autoimmune disease. Small joints of 
the hands and feet are affected most (more or the most) often; however, the disease is known 
to vary among individuals. In the general population, RA affects roughly three times more 
women (females) than men (males) and is more common between 35 and 50 years and in 
older individuals [65–68]. Persistent inflammation over time leads to joint damage and dis-
ability [69]. This disease is characterized by autoimmunity with multiple joint lesions and 
systemic inflammation. Also, patients can develop complications, which result in lifelong dis-
ability and increased mortality. Accordingly, RA is a growing public health concern as it is 
associated with significant social and economic burden [70].
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In genetically susceptible people, various environmental factors can act as a trigger for induc-
ing autoimmunity [71]. Recent experimental data showed that the pathogenesis of RA is asso-
ciated with epigenetic regulation. Over the past few years, it has become clear that different 
microRNAs (miRNAs) expression levels, particularly in RA, contribute to the development of 
autoimmunity. miRNAs plays (play) multiple roles in regulation of pro-inflammatory cyto-
kine secretion and development of immune cells, and they work in the induction or suppres-
sion of autoimmunity and ECM remodeling. Thus, dysregulated miRNA expression seems 
to promote the molecular mechanisms of the RA process [72–77]. Stanczyk et al. described 
for the first time the dysregulation of miRNAs in RA in 2008 [78]. They reported increased 
miR-155 and miR-146a expression in RA synovial fibroblasts compared to those in osteoar-
thritis (OA) patients. miRNAs expression is detected in several cell types in RA, and miRNAs 
expression profiles can regulate many physiological actions in RA (Table 1) [79, 80].
Cell type miRNA Refs.
Downregulated Upregulated
Synovial tissue miR-22 miR-146a [80–86]
miR-23b miR-146b
miR-30a miR-150
miR-155
miR-223
Synovial fibroblasts miR-124a miR-133a [85–91]
miR-34a miR-142-3p
miR-22 miR-142-5p
miR-152 miR-146a
miR-375 miR-155
miR-203
miR-221
miR-222
miR-323-3p
Synovial fluid miR-152 miR-16 [86, 92, 93]
miR-375 miR-146a
miR-155
miR-223
Synovium macrophages miR-146a miR-155 [81, 94]
Whole blood miR-99 [95, 96]
miR-100
miR-125b
miR-146a
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6. The roles of miRNAs in RA
Several miRNAs are found to be upregulated or downregulated in synovial tissue and cells of 
joint or blood compartment of patients with RA. The bone and joint destruction occurring in 
RA is accompanied by specific changes in cellular miRNAs that can affect epigenetic regula-
tion. The current literature demonstrates that a variety of miRNAs is frequently dysregulated 
in RA patients.
miR-15/miR-16: miR-15a/16-1 and miR-15b/16-2 are highly protected in mammalian species. 
miR-15a is downregulated in arthritic synovial tissue, which has a potential role in apoptosis 
[95]. Nagata et al showed that in synovium miR15a, expression levels are lower in diseased 
mice than in healthy controls [101]. miR-15 plays a role in apoptosis; it has a negative regula-
tory effect on Bcl-2. Sera of patients with early RA show differential levels of miR-16-1 and 
miR-16-2, which are increased in peripheral blood mononuclear cells (PBMC) of RA patients 
[86, 95, 98]. Besides, miR-16 is a good candidate as a marker of disease activity. It is one of the 
key pro-inflammatory (proinflammatory) mediators in RA: mir-16 being able to target “tumor 
necrosis factor-α” (TNF-α) may be the biomarker of the RA.
Cell type miRNA Refs.
Downregulated Upregulated
miR-155
Peripheral blood 
mononuclear cells (PBMCs)
miR-21 miR-26a [82, 96–98]
miR-132
miR-146a
miR-146b
miR-150
miR-155
miR-16
Plasma and serum miR-16 miR-16 [91, 95, 98–100]
miR-125a-3p miR-21
miR-126-3p miR-24
miR-132 miR-26a
miR-146a miR-125a-5p
miR-155 miR-125b
miR-126-3p
miR-223
miR-451
Table 1. Expression of miRNAs in RA.
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miR-17-92 cluster: It is a controller of apoptosis, lots of research groups found de-regulated 
expression of miRNAs within this cluster in the context of RA [102].
miR-18: miR 18a is upregulated in fibroblast-like synoviocytes (FLS) of RA patients. It is 
important in inflammation, because miR-18 contributes to NFκB mediated cartilage destruc-
tion and chronic inflammation in the joint through a positive feedback loop involving silenc-
ing of the “nuclear factor kappa-light-chain-enhancer of activated B cells” (NFκB) inhibitor 
TNF induced protein-3 [103].
miR-21: In RA patients, levels of miR-21 are raised in plasma [99]; on the other hand, one 
study showed that miR-21 level is decreased in peripheral blood mononuclear cells (PBMCs). 
Downregulation of miR-21 is related to upregulation of “signal transducer and activator of 
transcription 3” (STAT-3) expression and decreased “forkhead box P3” (FOXP 3) mRNA lev-
els in RA patients [104].
miR-22: Lin and his colleagues showed that expression of miR-22 is down regulated and neg-
atively correlated with Cyr61 expression in synovial tissue of RA patients [85]. CYR61 expres-
sion is high in RA FLS and stimulates RA synovial fibroblast proliferation and interleukin 
(IL)-6 secretion in an autocrine-paracrine manner [85]. CYR61 may encourage synovial tissue 
hyperplasia alongside IL-6-dependent Th17 differentiation, which is critical for joint lesions 
in RA.
miR-23b: miR-23b is reported to be decreased in RA. miR-23b expression level is reduced 
and correlated with the high concentration of IL-17 in tissue samples from RA patients [83]. 
IL-17 suppresses the expression of miR-23b in human primary FLS. miR-23b regulates IL-1β, 
TNF-α, and IL-17 signaling and decreased levels of miR-23b in RA may be responsible for the 
induction of autoimmune inflammation.
miR-24: In RA, increased levels of plasma miR-24 have been reported, also its level sig-
nificantly increased compared to OA [100]. Furin enzyme is important for the processing 
of latent TGF-β1, which may increase the inflammation by miR-24. Furin is a protein that 
is encoded by the FUR gene in humans. It was named FUR because it is in the upstream 
region of FES oncogene. Furin is also known as paired basic amino acid cleaving enzyme 
(PACE).
miR-26a: Murata and Nimoto worked with this molecule, and they showed that miR-26a is 
overexpressed in PBMCs and plasma of RA patients. Thus, it may be biomarker for the diag-
nosis of RA [82, 100]. miR-26a is upregulated during differentiation of IL-17 and generation of 
CD4+ cells. CD4+ cells are very important in the pathology of RA [82].
miR 27a and miR 27b: These miRNAs’ expression is decreased in OA chondrocytes and coin-
cides with increased expression of “Insulin Like Growth Factor Binding Protein 5” (IGFBP5) 
and Matrix Metallopeptidase-13 (MMP13) [105, 106].
miR-30a: miR-30a has been shown to be downregulated in RA synovial tissue and miR-30a-3p 
has a critical role in the regulation of “B lymphocyte activating factor of the tumor necrosis 
factor family” (BAFF) expression, which has a major impact in the regulation of the autoim-
mune responses occurring in RA [107].
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miR-34a/miR-34b: miR-34a and miR-34b family are investigated in RA. miR34a is downregu-
lated in RA synovial fibroblasts. The “X-linked inhibitor of apoptosis protein” (XIAP) is iden-
tified as a direct target of miR-34a [89]. So, miR-24 may contribute to the impaired apoptosis 
of activated RA synovial fibroblasts. On the other hand, miR-34b is overexpressed in RA T 
cells.
miR-124a: In 2009, Nakamachi et al. identified decreased expression levels of miR-124 in RA 
FLS. They showed that miR-24a targets the “monocyte chemoattractant protein-1” (MCP-1) 
mRNA expression and “cyclin-dependent kinase-2” (CDK-2) and decreases their protein lev-
els [88]. miR-124 controls inflammatory process in RA, indirectly. The curtailed expression of 
miR-124a can contribute to RA pathogenesis via increased RA synovial fibroblast prolifera-
tion, angiogenesis, and leukocyte chemotaxis [89].
miR-125a-3p/miR-125a-5p/miR-125b: The family of miR-125 is dysregulated in the periph-
eral blood of RA patients. Kim et al. found that miR-125a-5p and miR-125b activate the pro-
inflammatory NF-κB signaling pathway [108]. Thus, they may have roles in the induction of 
excessive inflammation in RA. Because of that, miRNA levels are monitored in serum from RA 
patients [95]. MiR-125b has a specific role in the regulation of normal and abnormal immune 
functions. Hruskova et al. suggested that the expression of miR-125b in those patients may 
present a novel biomarker for monitoring the treatment outcome during the early phase of 
RA [109].
miR-126-3p: miR-126-3p is significantly irregular in the plasma of RA patients. There is con-
flicting evidence regarding miR-126-3p. Wang et al. showed that miR-126-3p is lower in the 
plasma of RA patients [99], while another research group showed that the expression level 
of circulated miR-126-3p is markedly elevated in RA [100]. miR-126 can inhibit PI3K/AKT 
signaling pathway. It may clinically be helpful for RA patients [110].
miR-132: The expression of miR-132 of PBMCs from RA patients was twice higher as com-
pared to controls [45]. However, miR-132 concentrations were found to be lower in RA plasma 
than in the plasma of healthy individuals [86]. Plasma concentrations of miR-132 differenti-
ated patients with RA or OA from healthy controls, though plasma and synovial fluid miR-
132 failed to differentiate RA from OA. Besides, plasma miR-132 or its SF/PB ratio (ratio of 
concentration of synovial fluid miRNA to plasma miRNA) correlated with tender joint count. 
These results indicate that miR-132 may have a role in systemic conditions with joint inflam-
mation, such as RA [86]. miR-132 studies have mainly focused on central nervous system and 
neurotransmission; however, further analyses are required to determine the importance of 
miR-132 in inflammatory diseases [111].
miR-133a: MiR-133a is upregulated in RA synovial fibroblasts. Also, miR-133a is known as a 
negative regulator of the “Runt-related transcription factor 2” (Runx2), which is essential for 
the osteoblast differentiation [112].
miR146a/miR-146b: Studies showed that miR-146 is upregulated in all RA samples. One study 
found an increased basal expression of miR-146a in RA synovial fibroblasts compared with OA 
synovial fibroblasts [81, 87, 113]. In addition, increased expression levels of miR-146a have been 
observed in synovial fluid [85, 86, 97], synovial tissue [82, 83, 99], PBMCs [96, 97, 99, 114, 115], 
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and whole blood [96] of RA patients. Expression of miR-146a is detected in many cell types, T 
cells, B cells, monocytes, macrophages, and IL-17 producing CD4+ cells [81, 82, 97, 114, 115]. 
However, plasma or serum miR-146a levels in patients with RA are comparable to that seen in 
healthy controls [86, 98], and two studies demonstrated that miR-146a was markedly decreased 
in plasma from patients with established RA [99]. miR-146a can inhibit T-helper 1-mediated 
responses and is required for the suppressive activity of Treg cells, which are both important in 
RA pathogenesis [64, 115]. Nevertheless, the increasing expression of miR-146a is not specific 
to RA, as it is also reported in OA cartilage after stimulation by IL-1b [116].
Pauley and Abou-Zeid found that peripheral blood mononuclear cell expression of miR-146a 
was positively correlated with CRP, ESR, DAS28 index, and TNF-α concentration [97, 115]. 
There are two known gene targets of miR-146a, that is, TNF-α/TNF receptor-associated fac-
tor 6 (TRAF6) and IL-1 receptor-associated kinase 1 (IRAK1). Also, miRNA-146a can regulate 
genes such as FAF1, IRAK2, FADD, IRF-5, STAT-1, and PTC-1. However, miR-146a has also 
been reported to correlate inversely with the tender joint count [97, 115]. In addition, miRNA-
146a expression levels in the peripheral blood of RA patients were comparable to the levels 
seen in synovial tissue and fibroblastic cells of those patients [97]. miR-146a/b is induced in 
response to a variety of microbial components and pro-inflammatory cytokines, such as LPS, 
CpG, IFN-β, and TNF-α [51]. miR-146a in PBMCs enhances the function of Th1 cells and 
induces the expression of TNF-α, MCP-1, and NFκB p65 [117]. miR-146b was reported to 
increase in RA synovial tissue and in PBMCs of RA patients [82]. Upregulated miR-146b is 
related with infiltration of IL-17-producing T cells in RA synovium and higher expression of 
IL-17 within T cells expanded from RA PBMCs. So, it suggested that miR-146a and miR-146b 
are strongly implicated in RA development.
miR-152: Decreased expression of miR 152 is reported in FLS of arthritic rats. It leads to acti-
vation of the Wnt-signaling pathway through direct targeting of “DNA (cytosine-5)-methyl-
transferase-1” DNMT1 and “encoding Frizzled 8” (FZD8) by turn [92, 93].
miR-155: This is the most widely studied miRNA in RA. miR-155 expression profiles in 
RA synovial fibroblasts can also be induced by TNF-α [118]. The first miRNAs found to be 
abnormally expressed in FLS with RA were miR 146a and miR 155, both previously known as 
important regulators of inflammation. Also, miR 146a and miR 155 are two miRNAs, which are 
negative and positive regulators of inflammatory responses, respectively. miR-155 has been 
shown to express strongly in RA synovial tissue, synovial fluid and synovial fluid CD14+ cells 
[118]. Nonetheless, miR-155 concentrations are significantly lower as compared to controls in 
RA serum [98, 99]. The increased level of miR-155 in synovial fluid CD14+ cells and in synovial 
tissue macrophages is associated with decreased expression of the miR-155 target, a potent 
inhibitor of inflammation, called Src homology 2-containing inositol phosphatase-1 (SHIP-1), 
in patients with RA [94]. In addition, targets of miR-155 are the genes ZNF652, matrix metal-
loproteinase (MMP)-1 MMP-3, SHIP-1, c-Maf, PU.1, CEBP, ZIC3, HIVEP2, ARID2, SMAD5, 
and Bach-1. These pathways are all play a role in RA.
miR-203: One study showed that miR-203 is higher in RA synovial fluid in comparison with 
OA synovial fluid. Expression of miR-203 in the RA and OA synovium may be explained 
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by differences in cellular composition of synovial tissue among RA patients [67, 78, 91]. 
Overexpression of miR-203 in RA synovial fluid resulted in higher release of MMP-1 and 
secretion of IL-6 via the NF-κB pathway and NF-κB-dependent production of IL-6, thus con-
tributing to the RA synovial fluid activated phenotype and joint inflammatory state. Also, 
miR-203 plays a role in oncogenic transformation, proliferation, migration, and invasiveness 
of tumor cells. This mechanism is unknown in RA.
miR-221/miR-222: miR-221 and miR-222 are expressed together. miR-221/miR-222 are overex-
pressed in synovial fluids, blood serum, and synovial tissues of RA patients. MiR-221 plays 
a role in increasing production of pro-inflammatory cytokines, RA synovial fibroblast activa-
tion and migration. It also has a role in increasing resistance to apoptosis [119].
miR-223: miR 223 is increased in T cells from patients with RA compared to levels in T cells 
from healthy donors [120]. miR-223 overexpressed in peripheral blood CD3+ and CD4+ naive 
T-lymphocytes of RA patients contributes to pathogenesis of the disease. CD14+ monocytes 
from RA synovia also overexpress miR 223 and modulate differentiation of myeloid precur-
sors into osteoclasts [121].
miR-323-3p: miR-323-3p expression is higher in RA synovial fibroblasts than OA synovial 
fibroblasts [90]. This miRNA may increase the Wnt-cadherin pathway and decrease the levels 
of target protein “β-transducin repeat containing E3 ubiquitin protein ligase” (BTRC) that 
contains an inhibitor of β-catenin [90]. It has been shown that miR-323-3p may have pro-
inflammatory role in RA.
miR-375: miR-375 regulates the pathogenesis of adjuvant-induced arthritis rat model through 
the canonical Wnt signaling pathway [93].
miR-451: miR 451, most preserved in vertebrates, regulates cell proliferation, invasion, and 
apoptosis. Neutrophils are important players in RA pathogenesis. miR 451, significantly over-
expressed in RA serum, peripheral blood T cells from patients with active RA and downregu-
lated in neutrophils from patients with RA. Besides, it negatively regulates the migration of 
neutrophils by silencing CPNE3 (encoding copine3) and RAB5A (encoding Ras related pro-
tein Rab 5A) [122]. In RA, miR-451 may reduce neutrophil chemotaxis through p38 MAPK 
(p38 mitogen-activated protein kinases) [122].
miR-455-3p: miR-455-3p can drive cartilage degradation by suppressing the expression of 
key molecules involved in cartilage formation. Increased expression of miR 455 3p in OA car-
tilage contributes to its destruction by targeting ACVR2B (encoding activin receptor type 2B), 
SMAD2 (encoding MAD homology 2), CHRDL1 (encoding chordin like protein 1), and by 
suppressing TGF-β signaling [118].
miR-498: miR-498 is associated with neurotransmission and inflammation. miR-498 is down-
regulated in CD4+ T cells from synovial fluid and peripheral blood [85].
miR-886-3p: A recent study reported that the combination of low expression of miR-22 and 
high expression of miR-886-3p were predictive of a good clinical response to adalimumab 
treatment in patients with early RA [123].
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7. The importance of miRNAs in RA
MicroRNAs (miRNAs) are involved in the pathophysiological mechanisms underlying 
human diseases states. During the last decade, researchers have obtained a growing body 
of evidence regarding miRNAs in many human autoimmune diseases, such as RA, multiple 
sclerosis, psoriasis and systemic lupus erythematosus. miRNAs-mediated regulation is very 
clear from all of the present data and can play an important role in the development of vari-
ous inflammatory conditions. So, dysregulation of miRNA expression (loss or downregula-
tion of miRNA because of mutation, miRNA promoter region mutation, or overexpression of 
miRNA, epigenetic activation etc.) can lead to a variety of diseases.
For example, upregulation of miR-146 and miR-203 were observed in psoriasis [11]. Also, 
serum miR-1266 levels were highly significant in patients with psoriasis [124, 125]. Aberrations 
of miR-223, miR-143, miR-142, miR-378, miR-100, miR-21, and miR-31 levels were also found 
in these patients [126–128]. In systemic lupus erythematosus, some miRNAs, miR-146, miR-
17-5p, miR-112, miR-141, miR-184, miR-196a, miR-383, and miR-409-3p, are downregulated, 
but miR-21, miR-61, miR-78, miR-142-3, miR-189, miR-198, miR-298, miR-299-3p, and miR-
342 are upregulated in PBMCS from patients as compared to healthy controls [11, 127–131]. 
In multiple sclerosis, miR-18b, miR-599, and miR-96 are dysregulated in PBMCs in those 
patients [11, 132].
RA is a polygenic disease with multiple effects and miRNAs are post-transcriptional reg-
ulators of gene expression. In RA, high miRNA expressions (high mirna expressions mı 
olacak?) have been identified in different sites and cells, such as synovial tissue, synovial 
fibroblasts, PBMCs, plasma, synovial fluid, and activated immune cells within injured joints. 
The identified miRNA candidates for RA play a substantial role for key molecular mecha-
nisms. These mechanisms are especially cytokine signaling pathways and inflammation. So, 
miRNAs are upregulated or downregulated in RA patients, relative to other diseases and 
healthy controls.
miRNAs, as diagnostic tools for RA, have many advantages. As such, miRNAs are stable and 
can be isolated from different parts of bodies (synovial fibroblasts, blood, plasma). miRNAs 
can be detected in circulating blood without the need for biopsies. Finally, miRNAs expres-
sion levels can be estimated by PCR.
8. Conclusion and perspectives
Since the discovery that microRNAs (miRNAs) take part in biological and pathological pro-
cesses, it has become important to determine the roles.
In this chapter, we have summarized the role of miRNAs in RA. RA is a systemic autoim-
mune disorder characterized by chronic inflammation of the synovial tissue, and many stud-
ies suggest that miRNAs play role on autoimmunity in RA, as miR-16, miR-146b, miR-132, 
and miR-155 are upregulated in RA circulation. This suggests that miRNAs contribute to 
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RA pathogenesis. miR-124a is downregulated in RA synovium tissue [88] while miR-146a, 
miR-155 and miR-203 are upregulated in RA synovium tissue [51, 91, 133]. As we mentioned 
above, miR-146 and miR-203 are also upregulated in psoriasis; for this reason, they are ques-
tionable as possible biomarkers. miR-16, miR-132, miR-146, and miR-155 are upregulated in 
RA PBMCs, and miR-223 is upregulated in CD4+ naïve T-lymphocytes of RA patients [121].
Recently, the understanding of the molecular mechanism, prediction, or identification of 
miRNA targets is the main subjects of research in this area. This contribution may be lead to 
consider miRNAs as therapeutic targets. However, some miRNAs mentioned above are not 
specific for RA, as they are also dysregulated in the other immune disorders or cancers.
In the past few years, some experimental models have been used to study the therapeutic 
potential of miRNAs in RA, but still they are insufficient. Further studies are necessary.
In summary, each miRNA that is identified for RA opens the door slightly in terms of diag-
nostic and/or prognostic marker. Today, the available evidence shows that miRNAs are not 
diagnostic markers yet, but they can be used for therapy in the future.
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